

## HIPRA closes the first year of its CDMO with a first strategic contract

HIPRA's CDMO unit is already in advanced negotiation stages for several additional projects

**Girona, February 17, 2026** – HIPRA Biotech Services, HIPRA's unit dedicated to providing development and manufacturing services for biological products to biotechnology and pharmaceutical companies (CDMO), **has completed its first year of operations with results exceeding initial plans and with very positive growth prospects**. HIPRA introduced the unit in January 2025 and, in just 9 months, secured its first agreement, an especially relevant milestone in a sector characterized by long commercial cycles.

Launched with the aim of making HIPRA's knowledge and more than 50 years of experience in biotechnology available to third parties, as well as its scientific, technical, and industrial capabilities, **HIPRA Biotech Services offers advanced services for the development and production of biological products and vaccines. Its value proposition spans from R&D activities, optimization and industrial scale-up, from early research phases through to commercial-scale manufacturing**.

### Positive results validating the proposed strategy

In a market characterized by lengthy commercial processes that can take up to 18 months, HIPRA Biotech Services secured **its first contract** for the supply of a biological product for clinical studies with a **European biotechnology company** just **9 months after its launch**. In addition, the unit is in advanced negotiation stages for several additional projects. HIPRA Biotech Services was created with a **differentiated value proposition**, based on the combination of top-tier scientific, technical, and industrial capabilities, enabling it to provide high-quality, agile, and flexible support to its clients.

Currently, HIPRA, with over **50,000 m<sup>2</sup> of operational facilities**, has an installed capacity of **24,000 liters for microbial cultures**, as well as **2,000 liters of bioreactor capacity for mammalian cell cultures**, with an expansion underway that will allow for an increase to **8,000 liters in the next two years**. This is complemented by an **aseptic filling capacity of up to 90 million vials per year**.

The unit also has **R&D laboratories equipped with state-of-the-art technology**, prepared to support the entire lifecycle of biological product development—from cell line and manufacturing process development to analytical methods, scale-up, and industrial transfer.

“During this first year, we have participated in the main international congresses in the sector, a positioning we will maintain in 2026 to continue strengthening relationships with our clients, anticipating their needs and highlighting our differentiated capabilities as strategic partners in their projects,” said **Eduard Viladesau, General Manager of HIPRA Biotech Services**.

In terms of talent, the unit can leverage the knowledge and experience of approximately **400 professionals specialized in R&D and Operations in human and animal health**, integrated within the broader HIPRA Group ecosystem of more than **1,600 professionals**, combining human and animal health capabilities. This cross-functional approach provides flexibility, specialized expertise, and a differentiated perspective in service of HIPRA Biotech Services’ clients.

### **A strategic partner for biotechnological development**

In the short term, HIPRA Biotech Services aims to consolidate its position as a **strategic partner for innovative companies**, developing relevant projects for the sector and contributing to the **European Union’s strategic autonomy** by making advanced scientific and technical capabilities available from Spain. In the medium term, the unit’s objective is to become a **global benchmark in the biologics CDMO market**, driving health solutions that improve quality of life worldwide.

In this context, HIPRA estimates that HIPRA Biotech Services could represent between **15% and 20% of the Group’s total revenue in the medium term**, contributing significantly to its growth and diversification.

HIPRA’s accumulated experience places HIPRA Biotech Services in an excellent position to become a strategic partner for pharmaceutical and biotechnology companies seeking a CDMO to accelerate and increase the likelihood of success in the development of their products. HIPRA Biotech Services enters 2026 with strengthened enthusiasm and conviction following these initial milestones, as well as the humility to continue working intensively to meet the needs of both current and future clients.

## About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention in animal and human health (One Health), with a wide range of highly innovative vaccines and an advanced diagnostic service. With its claim **“Building immunity for a healthier world”**, HIPRA reaffirms its commitment to contributing solutions that improve global health. It has a strong international presence with **40 subsidiaries, 3 R&D centers and 6 production facilities** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network keeps commercial channels open in nearly 100 additional countries, thus covering all five continents.

Research and development are at the core of its expertise. HIPRA allocates **more than 15% of its annual revenue to R&D activities**, focused on the creation and application of the latest scientific advances for the development of innovative vaccines of the highest quality.

HIPRA has a portfolio of vaccines based on different technological platforms. Its R&D teams work with a wide range of technologies and biological modalities.

To add further value to its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

## Press contacts

### HARMON

Irene Calle – [icalle@harmon.es](mailto:icalle@harmon.es) – M. 609 873 052

José María Nieto – [jnieto@harmon.es](mailto:jnieto@harmon.es) – M. 689 186 062